Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.

European journal of clinical pharmacology - 1 Sept 2008

Rocha Adriana, Coelho Eduardo B, Moussa Soraia A P, Lanchote Vera L

Abstract excerpt

OBJECTIVE: This study compares midazolam with omeprazole as marker drugs for the evaluation of CYP3A activity in nine healthy self-reported white Brazilian volunteers. METHODS: Omeprazole was also used to evaluate the CYP2C19 phenotype. The volunteers received p.o. 20 mg omeprazole, and blood samples were collected 3.5 h after drug administration. After a washout period of 10 days, the volunteers received p.o. 15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Ulcer Agents
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Brazil

Share to Cytochrome P-450 CYP3A

Share to Metabolic Clearance Rate

Share to Midazolam

Share to Omeprazole

Share to Pharmaceutical Preparations

Source

Identifiers

PMID: 18581106
DOI: 10.1007/s00228-008-0510-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.PMID 18581106Read ↗

Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.Semantic proximity Read ↗

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.Semantic proximity Read ↗

Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.Semantic proximity Read ↗

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.Semantic proximity Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Semantic proximity Read ↗

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.Semantic proximity Read ↗

Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children.Semantic proximity Read ↗

Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?Semantic proximity Read ↗

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.Semantic proximity Read ↗

Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.Semantic proximity Read ↗

The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.